REFILE-BRIEF-Bayer's Nubeqa Receives EU Approval As Prostate Cancer Treatment - Reuters

March 30 (Reuters) - BAYER AG:

* NUBEQA® (DAROLUTAMIDE) RECEIVES EU APPROVAL AS A NEW TREATMENT FOR MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

* RESULTS FROM PRE-PLANNED FINAL OVERALL SURVIVAL ANALYSIS ARE EXPECTED TO BE PRESENTED AT AN UPCOMING SCIENTIFIC MEETING IN 2020 Source text: bit.ly/39AcB4Z Further company coverage: (Gdansk Newsroom)

Our Standards:The Thomson Reuters Trust Principles.


Comments

Popular posts from this blog

Sentinel lymph node biopsy: What cancer patients should know

Q&A

What Type of Cancer Causes Low Hemoglobin (Anemia)?